EXCLUSIVE LICENSE AGREEMENT between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA and RENOVIS, INC. for METHOD OF TREATING PAIN USING NALBUPHINE AND OPIOID ANTAGONISTS UC Case No. 2000-002Exclusive License Agreement • October 23rd, 2003 • Renovis Inc • Pharmaceutical preparations • California
This license agreement (the “Agreement”) is made and entered into effective as of December 27, 2002 (the “Effective Date”) by and between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, a California corporation having its statewide administrative offices at 1111 Franklin Street, Oakland, California 94607-5200, (“The Regents”), and acting through its Office of Technology Management, University of California San Francisco, 185 Berry Street, Suite 4603, San Francisco, CA 94107 (“UCSF”), and RENOVIS, INC., a Delaware corporation having a principal place of business at 270 Littlefield Avenue, South San Francisco, CA 94080 (the “Licensee”).
PATENT LICENSE AND RESEARCH COLLABORATION AGREEMENT between MERCK & CO., INC. and RENOVIS, INC.Patent License and Research Collaboration Agreement • October 23rd, 2003 • Renovis Inc • Pharmaceutical preparations • New York
THIS AGREEMENT (the “Agreement”), effective as of , 2003 (the “Effective Date”), is entered into by and between Merck & Co., Inc., a corporation organized and existing under the laws of the state of New Jersey (“MERCK”), and Renovis, Inc., a corporation organized and existing under the laws of the state of Delaware (“RENOVIS”).
THIRD AMENDMENT TO DEVELOPMENT, LICENSE AND MARKETING AGREEMENTLicense and Marketing Agreement • October 23rd, 2003 • Renovis Inc • Pharmaceutical preparations
This Third Amendment (the “Amendment”) to the Development, License and Marketing Agreement dated June 26, 1995, as amended, by and between Centaur Pharmaceuticals, Inc. and Astra AB (the “License Agreement”) is made this 18th day of June, 2002 by and between Centaur Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at 1220 Memorex Drive, Santa Clara CA 95050-2812 (“Centaur”) and AstraZeneca AB, successor to Astra AB, a corporation organized and existing under the laws of Sweden, S-151 85 Sodertalje, Sweden (“AstraZeneca”). Unless otherwise provided, all capitalized terms herein shall have the meaning as set forth in the License Agreement, including any exhibits or amendments thereto.
AMENDMENT TO DEVELOPMENT, LICENSE AND MARKETING AGREEMENT ENTERED INTO AS OF JUNE 26, 1995, AND MADE BY AND BETWEEN ASTRA AB AND CENTAUR PHARMACEUTICALS, INC.Development, License And • October 23rd, 2003 • Renovis Inc • Pharmaceutical preparations
This Amendment, entered into July 8, 1997, is made by1 and between Astra AB, a corporation organized and existing under the laws of Sweden, S-151 85 Sodertalje, Sweden (“Astra”) and Centaur Pharmaceuticals, Inc. a corporation organized and existing under the laws of the State of Delaware, 484 Oakmead Parkway, Sunnyvale, CA 94086, USA (“Centaur”).
AMENDMENT NO. 1 TO LICENSE AGREEMENTLicense Agreement • October 23rd, 2003 • Renovis Inc • Pharmaceutical preparations
WHEREAS, Centaur and Cutanix are parties to a License Agreement dated as of the 15th day of January, 1998 (the “License Agreement”); and
LICENSE AGREEMENTLicense Agreement • October 23rd, 2003 • Renovis Inc • Pharmaceutical preparations
This Agreement is made and entered into as of the 1/st/ day of January, 1998, by and among the OKLAHOMA MEDICAL RESEARCH FOUNDATION, an Oklahoma nonprofit corporation (“OMRF”), 825 N.E. 13th Street, Oklahoma City, Oklahoma 73104 (“Licensor”); and CENTAUR PHARMACEUTICALS, INC., a Delaware corporation (“Licensee”), having an office at 484 Oakmead Parkway, Sunnyvale, California 94086 (collectively the “Parties”).
FIRST AMENDMENT TO LICENSE AGREEMENTLicense Agreement • October 23rd, 2003 • Renovis Inc • Pharmaceutical preparations
This First Amendment to License Agreement (the “FIRST AMENDMENT”) is made and entered into as of this 29th day of June, 1995, by and among the OKLAHOMA MEDICAL RESEARCH FOUNDATION, an Oklahoma nonprofit corporation (“OMRF”), 825 N.E. 13th Street, Oklahoma City, OK 73104; THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, a Kentucky nonprofit corporation (“UKRF”), 120 Graham Avenue, Lexington, KY 40506-0051 (OMRF and UKRF are hereinafter collectively referred to as “LICENSORS”); and CENTAUR PHARMACEUTICALS, INC., a Delaware corporation, 484 Oakmead Parkway, Sunnyvale, CA 94086 (“LICENSEE”).
DEVELOPMENT, LICENSE AND MARKETING AGREEMENT BY AND BETWEEN ASTRA AB AND CENTAUR PHARMACEUTICALS, INC. DATED JUNE 26, 1995Development, License and Marketing Agreement • October 23rd, 2003 • Renovis Inc • Pharmaceutical preparations • New York
This Development, License and Marketing Agreement (the “LICENSE AGREEMENT”), entered into as of June 26, 1995 (the “EFFECTIVE DATE”), is made by and between
AMENDMENT TO SUPPLY AGREEMENTSupply Agreement • October 23rd, 2003 • Renovis Inc • Pharmaceutical preparations
This Amendment (the “Amendment”) to the Supply Agreement dated June 26, 1995, by and between Centaur Pharmaceuticals, Inc. and Astra AB (the “Supply Agreement”) is made this 18th day of June, 2002, by and between Centaur Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at 1220 Memorex Drive, Santa Clara CA 95050-2812 (“Centaur”) and AstraZeneca AB, successor to Astra AB, a corporation organized and existing under the laws of Sweden, S-151 85 Sodertalje, Sweden (“AstraZeneca”). Unless otherwise provided, all capitalized terms herein shall have the meaning as set forth in the Supply Agreement or License Agreement (each as defined below), including any exhibits or amendments thereto.
SUBLEASESublease • October 23rd, 2003 • Renovis Inc • Pharmaceutical preparations
THIS SUBLEASE, dated August 5, 2003, is entered into by and between TULARIK INC., a Delaware corporation (“Sublandlord”), and RENOVIS, INC., a Delaware corporation (“Subtenant”).
S U P P L Y A G R E E M E N TSupply Agreement • October 23rd, 2003 • Renovis Inc • Pharmaceutical preparations • New York
WHEREAS CENTAUR under a Development, License and Marketing Agreement (the “LICENSE AGREEMENT”) dated as of the Effective Date has granted ASTRA certain worldwide rights to exploit Licensed Product under the CENTAUR Technology and Product Know-How (all as more particularly set forth in the License Agreement); and
LICENSE AGREEMENTLicense Agreement • October 23rd, 2003 • Renovis Inc • Pharmaceutical preparations • California
THIS AGREEMENT is effective as of the 15th day of January, 1998 by and between CENTAUR PHARMACEUTICALS, INC., a corporation organized and existing under the laws of the State of Delaware and having its principal office at 484 Oakmead Parkway, Sunnyvale, California 94086 (“CENTAUR”), and CUTANIX CORPORATION, a corporation organized and existing under the laws of the State of Delaware, and having its principal office at 484 Oakmead Parkway, Sunnyvale, California 94086(“CUTANIX”).
SECOND AMENDMENT TO LICENSE AGREEMENT AND TERMINATION OF SERVICES AND SUPPLY AGREEMENTLicense Agreement • October 23rd, 2003 • Renovis Inc • Pharmaceutical preparations
THIS SECOND AMENDMENT TO LICENSE AGREEMENT AND TERMINATION OF SERVICES AND SUPPLY AGREEMENT (the “Amendment”) is made and entered into as of September 13, 2002 (the “Signing Date”) and shall become effective as of the Amendment Effective Date (as defined in Section 8.1 below), by and between CENTAUR PHARMACEUTICALS, INC., a Delaware corporation (“Centaur”) having its place of business at 1220 Memorex Drive, Santa Clara, CA 95050, and CUTANIX CORPORATION, a Delaware corporation (“Cutanix”) having its place of business at 1220 Memorex Drive, Santa Clara, CA 95050.
LICENSE AGREEMENTLicense Agreement • October 23rd, 2003 • Renovis Inc • Pharmaceutical preparations
This Agreement is made and entered into as of the 15th day of July, 1992, by and among the OKLAHOMA MEDICAL RESEARCH FOUNDATION, an Oklahoma nonprofit corporation (“OMRF”), 825 N.E. 13th Street, Oklahoma City, Oklahoma 73104; THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, a Kentucky nonprofit corporation (“UKRF”), 120 graham avenue, Lexington, Kentucky 40506-0051 (OMRF and UKRF are hereinafter referred to together as “Licensors”); and CENTAUR PHARMACEUTICALS, INC., a delaware corporation (“Licensee”), having an office at 1250 coast Village Road, Suite K, Santa Barbara, California 93108.
